Saudi Central Bank Grows Stock Position in Gilead Sciences, Inc. $GILD

Saudi Central Bank raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 89.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 86,886 shares of the biopharmaceutical company’s stock after buying an additional 41,091 shares during the quarter. Saudi Central Bank’s holdings in Gilead Sciences were worth $10,977,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Fortitude Advisory Group L.L.C. lifted its position in shares of Gilead Sciences by 7.0% during the 2nd quarter. Fortitude Advisory Group L.L.C. now owns 1,769 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 115 shares during the last quarter. Compass Financial Management LLC bought a new stake in Gilead Sciences in the 2nd quarter valued at about $671,000. AlphaGrep UK Ltd bought a new stake in Gilead Sciences in the 2nd quarter valued at about $658,000. Maloon Powers Pitre Higgins & Dennehy LLC purchased a new stake in Gilead Sciences during the second quarter valued at about $361,000. Finally, Markowski Investments purchased a new stake in Gilead Sciences during the second quarter valued at about $100,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on GILD shares. Royal Bank Of Canada increased their target price on shares of Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research report on Wednesday, August 5th. Wall Street Zen lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Saturday. Daiwa Securities Group cut their price objective on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, May 19th. Barclays reduced their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 29th. Finally, Weiss Ratings cut shares of Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $158.04.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: New HIV and oncology approvals broaden Gilead’s growth prospects. FDA approval of Bixlenvo, a once-daily single-tablet HIV regimen for virologically suppressed adults on complex treatments, could strengthen the company’s HIV franchise. Separately, European approval of Trodelvy plus Keytruda for certain first-line metastatic triple-negative breast cancer patients expands Gilead’s oncology opportunity. Commercial uptake will determine the ultimate revenue impact. HIV and oncology approvals article
• Positive Sentiment: Analysts raised long-term earnings expectations. Zacks Research increased its Q1 2028 EPS estimate to $2.15, Q2 2028 to $2.31 and FY2028 to $9.66, while maintaining a “Strong Buy” rating. The revisions suggest improving confidence in Gilead’s future profitability. Gilead analyst estimates
• Positive Sentiment: An Arcus-backed cancer study reached completion. The milestone sets up a potentially important immuno-oncology catalyst, although investors will likely need to wait for efficacy and safety data before assigning significant value to the program. Arcus-backed cancer trial article
• Neutral Sentiment: Gilead continues to support income investors with a $0.82 quarterly dividend. The $3.28 annualized payout provides shareholder support, but the high payout relative to reported earnings makes future dividend growth dependent on sustained HIV cash flow and successful new-product launches. Gilead dividend article
• Neutral Sentiment: CEO Daniel O’Day sold $2.23 million of stock. The 15,000-share sale reduced his holdings by 2.53%, but it was completed under a pre-arranged Rule 10b5-1 plan, limiting its value as a bearish signal. SEC insider trading filing
• Negative Sentiment: Investors remain concerned about concentration and patent-expiration risk. Gilead’s dividend and cash generation depend heavily on its leading HIV franchise, particularly a blockbuster therapy facing a known patent expiration later in the next decade. The sharp decline in cell-therapy licensing deals also highlights uncertainty around diversification beyond HIV. Gilead dividend and patent risk article

Gilead Sciences Stock Down 0.2%

Shares of NASDAQ GILD opened at $150.99 on Friday. Gilead Sciences, Inc. has a 12 month low of $108.46 and a 12 month high of $157.29. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $187.22 billion, a price-to-earnings ratio of -56.55 and a beta of 0.33. The business has a 50-day moving average of $136.67 and a 200-day moving average of $136.52.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. During the same period last year, the firm posted $2.01 earnings per share. Gilead Sciences’s quarterly revenue was up 10.6% on a year-over-year basis. Sell-side analysts expect that Gilead Sciences, Inc. will post -0.48 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. Gilead Sciences’s dividend payout ratio is presently -122.85%.

Insider Activity

In other news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the sale, the director directly owned 10,066 shares of the company’s stock, valued at approximately $1,459,771.32. The trade was a 33.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the transaction, the insider owned 118,234 shares of the company’s stock, valued at $16,273,727.76. This trade represents a 19.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 105,000 shares of company stock worth $14,495,820. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.